Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
China-Originated Assets Lead Global GLP-1 Deals
Differentiation A Key Consideration
Aug 20 2025
•
By
Xu Hu
Fierce domestic R&D competition is driving Chinese firms' differentiated GLP-1 assets but not all developers may be able to strike cross-border deals
(Shutterstock)
More from Deals
More from China